Change in high-sensitive cardiac troponin T on hypertensive treatment

Clinical and Experimental Hypertension

Volumn 35, Issue 1, 2013, Pages 40-44

  Hoshide, Satoshi ^a   Fukutomi, Motoki ^a   Eguchi, Kazuo ^a   Watanabe, Tomonori ^a   Kabutoya, Tomoyuki ^a   Kario, Kazuomi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

A highly sensitive assay for cardiac troponin T; Angiotensin II type I receptor blocker; Calcium channel blocker; Hydrochlorothiazide; Hypertension

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; TROPONIN T;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; COMPARATIVE EFFECTIVENESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HYPERTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; TROPONIN T;

EID: 84871787986     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2012.689044     Document Type: Article

References (23)

1. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54: 1084-1091.
2. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. J Am Med Assoc 1996; 275: 1507-1513.
3. Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009; 361:2538-2547.
4. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010; 56:254-261.
5. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. J Am Med Assoc 2010; 304:2503-2512.
6. Fukutomi M, Hoshide S, Eguchi K, Watanabe T, Shimada K, Kario K. Differential effects of strict blood pressure lowering by losartan/ hydrochlorothiazide combination therapy and high-dose amlodipine monotherapy on microalbuminuria: the ALPHABET study. J Am Soc Hypertens 2012; 6:73-82.
7. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53:982-992.
8. Saenger AK, Beyrau R, Braun S, et al. Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clin Chim Acta 2011; 412:748-754.
9. DeFilippi CR, De Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. J Am Med Assoc 2010; 304:2494-2502.
10. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998; 7:176-183.
11. Sawada T, Yamada H, Dahlof B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009; 30:2461-2469.
12. Yamamoto K, Ozaki H, Takayasu K, et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertens Res 2010; 34:325-330.
13. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based onvalsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
14. Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48:385-391.
15. Camici PG, Crea F. Coronary microvascular dysfunction.NEngl J Med 2007; 356:830-840.
16. Hittinger L, Mirsky I, Shen YT, Patrick TA, Bishop SP, Vatner SF. Hemodynamic mechanisms responsible for reduced subendocardial coronary reserve in dogs with severe left ventricular hypertrophy. Circulation 1995; 92:978-986.
17. Escalon JC, Wong SS. False-positive cardiac troponin T levels in chronic hemodialysis patients. Cardiology 1996; 87:268-269.
18. Croitoru M, Taegtmeyer H. Spurious rises in troponin T in endstage renal disease. Lancet 1995; 346:974.
19. Mockel M, Schindler R, Knorr L, et al. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: a 9-month outcome analysis. Nephrol Dial Transplant 1999; 14:1489-1495.
20. Van Lente F, McErlean ES, DeLuca SA, Peacock WF, Rao JS, Nissen SE. Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case-matched study. J Am Coll Cardiol 1999; 33:471-478.
21. Davis GK, Labugger R, Van Eyk JE, Apple FS. Cardiac troponin T is not detected in Western blots of diseased renal tissue. Clin Chem 2001; 47:782-783.
22. Taniguchi R, Sato Y, Yamada T, et al. Combined measurements of cardiac troponin T and N-terminal pro-brain natriuretic peptide in patients with heart failure. Circ J 2004; 68:1160-1164.
23. Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 2007; 116: 249-257.